Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate ...

Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...

The One Medicine Platform replaces 20+ legacy platforms—unifying medicinal development processes & data sources into a ...

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch ...

With VAXXITEK ® HVT+IBD+H5, Boehringer Ingelheim is expanding its proven VAXXITEK ® range with a new vaccine that protects against three severe poultry diseases: Marek's disease, Infectious Bursal ...

NAIROBI, Kenya, Feb 26 – Boehringer Ingelheim, the Germany-based research-driven biopharmaceutical company, has signed a Memorandum of Understanding (MoU) with Kenya’s Mission for Essential Drugs and ...

Boehringer Ingelheim and ExpressionEdits will collaborate on the optimization of the expression of gene therapies ExpressionEdits announced a collaboration and licensing agreement with Boehringer ...

Boehringer Ingelheim has announced a Phase III trial of its investigational lung disease drug nerandomilast has met its primary endpoint. Image credit: Tada Images / Shutterstock Boehringer ...

Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung juries. November 22 ...